Clinical Trial Update: Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 [Phase 2]

View source ↗

Summary

This report documents the completion of a Phase 2 trial evaluating trastuzumab in combination with paclitaxel for metastatic breast cancer overexpressing HER2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxol (paclitaxel)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED